Real-time Stock quotes, portfolio, LIVE TV and more.
Sun Pharma is to announce its Q4FY07 result. According to CNBC-TV18 estimates, the company is expected to post Q4 net profit of Rs 190.9 crore versus Rs 142.8 crore, up 34% on YoY basis.
The net sales of the company are expected to go up by 28% at Rs 518.9 crore versus Rs 405.4 crore in the corresponding quarter previous year.
Q4FY07 YoY (consolidated)
- Net sales up 28% at Rs 518.9 Cr vs Rs 405.4 Cr
- Operating profit at Rs 165 Cr vs Rs 96.9 Cr
- OPM at 32% vs 24%
- Net profit up 34% at Rs 190.9 Cr vs Rs 142.8 Cr
FY07 YoY (consolidated)
- Net sales up 26.37% at Rs 2066.8 Cr vs Rs 1635.9 Cr
- Operating profit 38% at Rs690Cr vs Rs497.4Cr
- OPM at 33% vs 29%
- Net profit up 37.9% at Rs 790.50Cr vs Rs572.9Cr
Factor to watch for
-Exports likely to surge due to growth in formulation exports powered by strong sales from its US subsidiary Caraco
-Good growth in domestic sales expected
-EBIDTA margins are expected to improve sharply on account of low base last year, which was impacted by one-time acquisition related expenses
-The progress on integration benefits of acquisition of Able Pharma
-Could make come acquisitions as it has strong cash balance of US $500mn of cash on its balance sheet (However big ticket acquisition is unlikely due to managements reluctance to participate in high-profile bidding wars).
-De-merged R&D entity SPARC (will list soon - listing date not fixed )
-R&D pipeline is valued at US$250m toUS$300m which is Rs 50- 65 per share
-With earliest expected launch in 2009 for one of the NDDS product
-R&D cost as a percentage of sales will come down significantly to the parent Sun Pharma (8% of total sales in FY06)
Sales Break up:
-Domestic formulation 52%
-Domestic bulk drugs 4%
-Export bulk drug 10%
- Export formulation 34%
Tags: Sun Pharma
May 21 2013, 13:56
- in Results Boardroom
May 21 2013, 11:05
- in MARKET OUTLOOK